Regulus Therapeutics
RGLS
#6888
Rank
โ‚ฌ0.49 B
Marketcap
7,12ย โ‚ฌ
Share price
0.00%
Change (1 day)
409.91%
Change (1 year)

Regulus Therapeutics (RGLS) - Total liabilities

Total liabilities on the balance sheet as of March 2025 : โ‚ฌ5.05 Million

According to Regulus Therapeutics's latest financial reports the company's total liabilities are โ‚ฌ5.05 Million. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Regulus Therapeutics - Total liabilities on balance sheet (from 2011 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚ฌ7.46 M-13.65%
2023-12-31โ‚ฌ8.65 M-30.88%
2022-12-31โ‚ฌ12.51 M5.02%
2021-12-31โ‚ฌ11.91 M26.6%
2020-12-31โ‚ฌ9.41 M-52.21%
2019-12-31โ‚ฌ19.69 M-33.29%
2018-12-31โ‚ฌ29.52 M-16.82%
2017-12-31โ‚ฌ35.49 M-16.25%
2016-12-31โ‚ฌ42.38 M172.55%
2015-12-31โ‚ฌ15.55 M-52.07%
2014-12-31โ‚ฌ32.45 M51.36%
2013-12-31โ‚ฌ21.43 M-31.54%
2012-12-31โ‚ฌ31.31 M-51.8%
2011-12-31โ‚ฌ64.97 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Sanofi
SNY
โ‚ฌ57.60 B 1,138,690.96%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚ฌ9.75 B 192,771.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ62.41 B 1,233,635.77%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ57.02 B 1,127,099.03%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚ฌ53.47 B 1,056,892.07%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
โ‚ฌ71.89 M 1,321.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚ฌ3.64 B 71,944.84%๐Ÿ‡บ๐Ÿ‡ธ USA